Welcome to BlogNotions' Life Sciences Blog

The BlogNotions Life Sciences Blog delivers a diverse series of perspectives provided by thought leaders in the life sciences industries. Presented by NetLine, this forum delivers compelling updates on the latest technological advances, discussions of research and findings, best practices for advancing education, implications for the future of various life sciences fields, and much more. Here you can find helpful information, ask questions, and collaborate freely.

Flexion Therapeutics Announces FDA Approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis Knee Pain

In continuation of my update on Zilretta  Flexion Therapeutics, Inc. announced,  that  Food and Drug Administration (FDA) approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection for osteoarthritis knee pain. Zilretta is a non-opioid medicine that employs Flexion’s proprietary microsphere technology to provide proven pain relief over 12 weeks. “The approval […]

Continue Reading

FDA Approves Lyrica CR (pregabalin) Extended-Release Tablets for Neuropathic Pain Conditions

In continuation of my update on Pregabalin Pfizer Inc.  announced today that the  Food and Drug Administration (FDA) has approved Lyrica CR (pregabalin) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN). Lyrica CR did not receive approval for the management of fibromyalgia. “Lyrica CR was developed […]

Continue Reading

Drug Patent Expirations for Oct 12, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. EFFIENT (prasugrel hydrochloride) Eli Lilly And Co Patent number: 5,288,726 Expiration Date: Oct 14, 2017 BYETTA (exenatide synthetic) Astrazeneca Ab Patent number: 7,297,761 Expiration Date: Oct […]

Continue Reading

Discussing Biotechnology Commercialization at UT Arlington

I will be giving a pair of talks on biotechnology commercialization at the University of Texas at Arlington on November 2nd and 3rd (for more on my speaking engagements see https://www.thinkbiotech.com/ ). If you are in the area and would like more information, please contact me. To arrange for a talk on global biotechnology (based on my […]

Continue Reading

Drug Patent Expirations for Oct 5, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. AGGRASTAT (tirofiban hydrochloride) Medicure Patent number: 5,978,698 Expiration Date: Oct 8, 2017 DrugPatentWatch provides instant access to actionable insights on pharmaceutical drugs. For more information try […]

Continue Reading

Drug Patent Expirations for Sep 28, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. OCTREOSCAN (indium in-111 pentetreotide kit) Mallinkrodt Nuclear Patent number: 6,123,916 Expiration Date: Sep 26, 2017 SYMBICORT (budesonide; formoterol fumarate dihydrate) Astrazeneca Patent number: 6,123,924 Expiration Date: […]

Continue Reading

Heparin promotes food intake and body weight gain in animal models

In continuation of my update on Heparin…..………………………………… Heparin is a medication widely used to prevent blood clotting; it is named after and mimics the naturally occurring anticoagulant in the body. However, research published today in Cell Reports shows a novel role of heparin as a promoter of food intake and body weight increase in animal models. These […]

Continue Reading

Mild pain killer blocks action of key protein required for hearing

In continuation of my update on ‘diflunisal‘ A Rice University study has found that the aspirin-like drug diflunisal blocks the action of prestin, a key protein that is required for hearing. The research, which is available online in the open-access journal PLOS ONE, stemmed from a 2015 Rice study that screened more than a half-dozen nonsteroidal […]

Continue Reading

Cancer drug may inhibit growth of cysts in patients with inherited form of kidney disease

In continuation of my update on bostinib A cancer drug called bosutinib may inhibit the growth of cysts in patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings point to a potential new treatment strategy for affected […]

Continue Reading

New drug shows promising results for treating spinal muscular atrophy

A drug developed by an Iowa State University biomedical researcher as a potential treatment for spinal muscular atrophy showed promising results in a recently published study. Ravindra Singh, a professor of biomedical sciences in the ISU College of Veterinary Medicine, has been studying spinal muscular atrophy, a leading genetic cause of infant mortality, for years. […]

Continue Reading